Aktienanalyse zu Tactile Systems Technology Inc (TCMD)TCMDTactile Systems Technology Inc

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Tactile Systems Technology Inc is a good buy right now due to its current price of $22.52, which is significantly lower than the analyst price target of $36, indicating a potential upside of 60%. Additionally, the company has shown strong revenue growth with Q2 2026 revenue at $85.7 million, a 9% year-over-year increase, and a gross margin of 76.3%. The main risk is the recent decline in stock price, with a 1-year change of +54.14% and a year-to-date change of -17.81%, indicating volatility.

6 analysts cover TCMD: 6 rate it Buy, 0 Hold and 0 Sell. The average price target is 31.67.